



Weill Cornell Medicine

DnD-Seq: A Versatile Platform for High-Resolution Protein-DNA Interaction Mapping in Single Cells

Lead Inventors:

Dan Landau, M.D., Ph.D.

Associate Professor of Medicine, Division of Hematology and Medical Oncology

Associate Professor of Physiology and Biophysics, Weill Cornell Medicine

Core Member, New York Genome Center

Business Development Contact:

Jamie Brisbois

Manager, Business Development and Licensing

(646) 921-4743

jamie.brisbois@cornell.edu

DnD-Seq: A Versatile Platform for High-Resolution Protein-DNA Interaction Mapping in Single Cells

Background & Unmet Need

- Over 1,600 transcription factors orchestrate gene regulation through complex DNA interactions, which are often disrupted in disease and aging
- Current bulk methods like ChIP-seq and CUT&TAG require stringent conditions that disrupt weaker protein-DNA interactions and mask cellular heterogeneity by providing only population averages
- While techniques like DamID can map protein-DNA interactions genome-wide, they cannot capture the dynamic regulatory networks at single-cell resolution needed to understand cell-type specific responses and disease mechanisms
- **Unmet Need:** Methods that can directly identify and map non-histone protein binding events with single-cell resolution

Technology Overview

- **The Technology:** A sequencing method (DnD-seq) that combines nanobody-directed targeting with controlled DNA deamination to record protein-DNA binding events at single-cell resolution
- The technology utilizes an engineered split DddA enzyme with nanobody targeting enables controlled, protein-specific DNA modification that permanently marks binding sites
- The system remains inactive until deliberately activated, ensuring specific recording of protein-DNA interactions
- **PoC Data:** Demonstrated high specificity with clear identification of transcription factor footprints and concordance with ChIP-seq reference data
- Demonstrated CTCF profiling in primary human CD8 T cells, revealing how IDH2 mutations alter CTCF binding patterns and chromatin organization across different cell types, validated by genotype-specific analysis

Inventors:

Dan Landau
Ivan Raimondi
Wei-Yu Chi

Patents:

[PCT Filed](#)

Publications:

[Chi et al. Cell. 2026](#)

Biz Dev Contact:

Jamie Brisbois
(646) 921-4743
jamie.brisbois@cornell.edu

Cornell Reference:

D-11042



Weill Cornell Medicine

DddA: Double-stranded DNA deaminase A
CTCF: CCCTC-binding factor I
DH2: Isocitrate dehydrogenase 2

DnD-Seq: A Versatile Platform for High-Resolution Protein-DNA Interaction Mapping in Single Cells

Technology Applications

- Enhanced AI/ML cell modeling through high-resolution protein-DNA interaction data
- Optimization of chromatin-targeted therapeutic development
- Improved detection of off-target effects in genetic engineering
- Advanced cellular reprogramming through precise transcription factor mapping

Technology Advantages

- Integration with diverse platforms (PTA, DLP, 10X Multiome) for comprehensive analysis
- Enables simultaneous profiling of protein binding and chromatin accessibility at single-cell resolution
- Reveals cellular heterogeneity previously masked in bulk approaches
- Expandable platform allowing incorporation of additional protein-specific nanobodies

Supporting Data / Figures




Figure 1: Schematic representation of the DnD-seq split enzyme system. The engineered construct comprises an inactive DddA N-terminal domain fused to a nanobody that recognizes target antibodies, and a separate C-terminal domain. When brought together at antibody-bound transcription factor (TF) sites, the enzyme becomes active.

Inventors:

Dan Landau
Ivan Raimondi
Wei-Yu Chi

Patents:

[PCT Filed](#)

Publications:

[Chi et al, Cell, 2026](#)

Biz Dev Contact:

Jamie Brisbois
(646) 921-4743
jamie.brisbois@cornell.edu

Cornell Reference:


D-11042



Weill Cornell Medicine

DnD-Seq: A Versatile Platform for High-Resolution Protein-DNA Interaction Mapping in Single Cells

Supporting Data / Figures



Inventors:

Dan Landau
Ivan Raimondi
Wei-Yu Chi

Patents:

[PCT Filed](#)

Publications:

[Chi et al. Cell. 2026](#)

Biz Dev Contact:

Jamie Brisbois
(646) 921-4743
jamie.brisbois@cornell.edu


Cornell Reference:

D-11042

DnD-Seq: A Versatile Platform for High-Resolution Protein-DNA Interaction Mapping in Single Cells

Supporting Data / Figures

CD8 T Cells : n = 7546



CTCF differential binding




Figure 3: Left: Cell clustering analysis showing clear separation of CD8 T cells into two distinct populations - one enriched for IDH2 wild-type cells and another for IDH2 mutant cells.

Right: Analysis of CTCF binding differences between wild-type and mutant cells. Red dots highlight regions where CTCF binding is significantly different, with most showing decreased binding in mutant cells.

Inventors:

Dan Landau
Ivan Raimondi
Wei-Yu Chi

Patents:

[PCT Filed](#)

Publications:

[Chi et al. Cell. 2026](#)

Biz Dev Contact:

Jamie Brisbois
(646) 921-4743
jamie.brisbois@cornell.edu

Cornell Reference:

D-11042



Weill Cornell Medicine